Sodium-Glucose Co-transporter-2 (SGLT-2) inhibitors are the only medications that have shown prognostic efficacy in all patients with heart failure regardless of diabatic status, or EF pertaining to HF hospitalizations and cardiovascular mortality [6, 36]. The gene discussed is SLC5A2; the disease is heart failure.